Research
Hormonal
GLP-1 receptor agonists have good safety and tolerability compared to traditional hypoglycemic drugs.
Practitioners can consider GLP-1 receptor agonists as a safer alternative for diabetes treatment.
StrongSupportsmedium confidence
Compared with traditional hypoglycemic drugs, GLP-1 receptor agonists have good safety and tolerability.
Why this rating
The claim is based on a review of recent research progress.
Source
The Discovery and Development of Glucagon-Like Peptide-1Receptor Agonists
Haowen Fang et al. · Current Medicinal Chemistry · 2023
DOI 10.2174/0929867330666230416153301
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →